KF 072

Drug Profile

KF 072

Alternative Names: KF-072

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Akeso Biopharma
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 14 Sep 2017 KF 072 is available for licensing as of 14 Sep 2017. http://www.akesobio.com/index.php?siteid=2
  • 14 Sep 2017 Early research in Inflammation in China (unspecified route) (Akeso Biopharma pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top